Researchers studied South African medicinal plants for bioactive compounds inhibiting SARS-CoV-2 binding to ACE2 receptors. Identified promising compounds like sesaminol glucoside could lead to new phytotherapeutics.
Schisandrin B from Schisandra fruit inhibits Angiotensin II-induced cardiac inflammation and remodeling by targeting MyD88. Potential novel therapy for myocardial inflammatory diseases.
Researchers identified natural products, such as salvinorin A and deacetylgedunin, as potential anti-SARS-CoV-2 agents using computational methods. These compounds show promise in inhibiting viral replication and cell entry, providing a potential supplement to vaccination efforts against COVID-19.
Nanoparticles loaded with Triphala (nanotriphala) show promise as a anti-inflammatory therapy for COVID-19. Chebulagic acid and chebulinic acid are the active compounds reducing cytokine release and inflammation.
Study found lectins MVL and Jacalin have strong binding affinity to spike protein of original and mutant SARS-CoV-2 strains, offering potential for anti-SARS-CoV-2 drugs. This research supports development of natural product-based treatments for COVID-19 and other infectious diseases.
Researchers developed a model of ARDS and PF caused by SARS-CoV-2 in cells. HIF-1α knockdown and apigetrin showed promise in reducing inflammation and fibrosis, suggesting potential for SARS-CoV-2 treatment.
Researchers investigated the potential of L. (L.)-mediated phytocompounds for treating SARS-CoV-2. Top candidates myricitrin, engeletin, astilbin showed stable binding and favorable pharmacokinetics in silico, suggesting potential as safe COVID-19 therapies.
Researchers developed a chromatographic method using an immobilized ATR to identify bioactive compounds in Tibetan medicine. Naringenin, pinocembrin, and chrysin were found to specifically bind to ATR, showing potential for drug development.